Literature DB >> 23149418

Validity and reliability of new intravascular ultrasound analysis software for morphological measurement of coronary artery disease.

Naoki Nakayama1, Kiyoshi Hibi, Mitsuaki Endo, Akiyoshi Miyazawa, Hiroyuki Suzuki, Nobuhiko Maejima, Takaaki Isshiki, Ken Kozuma, Kazuo Kimura.   

Abstract

BACKGROUND: Intravascular ultrasound (IVUS) analysis software enables precise planimetry measurement and tissue characterization of coronary plaque. Recently, a new IVUS analysis software compatible with integrated backscatter-IVUS, VISIATLAS(TM), was developed. The validity and reliability of VISIATLAS(TM) were evaluated. METHODS AND
RESULTS: Forty patients who underwent IVUS-guided percutaneous coronary intervention were enrolled, and planimetry measurements were performed by 2 observers using VISIATLAS(TM) and echoPlaque(TM). IVUS analysis was performed in non-stent segments in 10 patients (non-target vessel, n=5; target vessel before stent implantation, n=5) at every 2.5mm for 20 slices in each patient. Stent segments were analyzed in the remaining 30 patients. With VISIATLAS(TM), the intraobserver and interobserver intraclass correlation coefficients (ICC) for the area of external elastic membrane (EEM), lumen, and plaque plus media (P+M) were 0.999 and 0.999, 0.996 and 0.993, and 0.993 and 0.991, respectively. The intersoftware ICC for EEM, lumen, and P+M area were 0.997, 0.993, and 0.985, respectively. The ICC of stent volume for intraobserver, interobserver and intersoftware comparisons were 0.997, 0.993, and 0.998, respectively. Bland-Altman plots showed small differences and narrow limits of agreement for all of the above parameters.
CONCLUSIONS: VISIATLAS(TM) has high repeatability and reproducibility of measurement. This new IVUS analysis software is suitable for accurate measurement of coronary artery and stent structure in future IVUS studies.

Entities:  

Mesh:

Year:  2012        PMID: 23149418     DOI: 10.1253/circj.cj-12-0630

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  5 in total

1.  Effects of sitagliptin on coronary atherosclerosis in patients with type 2 diabetes-A serial integrated backscatter-intravascular ultrasound study.

Authors:  Tsuyoshi Nozue; Kazuki Fukui; Yutaka Koyama; Hiroyuki Fujii; Tomoyuki Kunishima; Hiroyuki Hikita; Kiyoshi Hibi; Akiyoshi Miyazawa; Ichiro Michishita
Journal:  Am J Cardiovasc Dis       Date:  2016-11-30

2.  Impact of the triglyceride level on coronary plaque components in female patients with coronary artery disease treated with statins.

Authors:  Motoki Yamashita; Atsushi Iwata; Yuta Kato; Makito Futami; Satoshi Imaizumi; Takashi Kuwano; Amane Ike; Makoto Sugihara; Hiroaki Nishikawa; Bo Zhang; Shin'ichiro Yasunaga; Keijiro Saku; Shin-Ichiro Miura
Journal:  Heart Vessels       Date:  2018-04-25       Impact factor: 2.037

3.  Impact of von Willebrand factor on coronary plaque burden in coronary artery disease patients treated with statins.

Authors:  Yuta Kato; Atsushi Iwata; Makito Futami; Motoki Yamashita; Satoshi Imaizumi; Takashi Kuwano; Amane Ike; Makoto Sugihara; Hiroaki Nishikawa; Bo Zhang; Shin'ichiro Yasunaga; Keijiro Saku; Shin-Ichiro Miura
Journal:  Medicine (Baltimore)       Date:  2018-04       Impact factor: 1.889

4.  Association between blood glucose variability and coronary plaque instability in patients with acute coronary syndromes.

Authors:  Kozo Okada; Kiyoshi Hibi; Masaomi Gohbara; Shunsuke Kataoka; Keiko Takano; Eiichi Akiyama; Yasushi Matsuzawa; Kenichiro Saka; Nobuhiko Maejima; Mitsuaki Endo; Noriaki Iwahashi; Kengo Tsukahara; Masami Kosuge; Toshiaki Ebina; Peter J Fitzgerald; Yasuhiro Honda; Satoshi Umemura; Kazuo Kimura
Journal:  Cardiovasc Diabetol       Date:  2015-08-20       Impact factor: 9.951

5.  Comparison of quantitative measurements between two different intravascular ultrasound catheters and consoles: in vitro and in vivo studies.

Authors:  Hiroyuki Okura; Makoto Watanabe; Akihiro Miura; Muneo Kurokawa; Tomoya Ueda; Tsunenari Soeda; Yoshihiko Saito
Journal:  Cardiovasc Interv Ther       Date:  2021-02-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.